Sarepta Therapeutics' shares plunged nearly 30% on Tuesday as the failure of two of its approved drugs in a key trial and ...

The United States on Tuesday imposed sanctions on a group of bankers, financial institutions and others accused of laundering ...

US stocks fell on Tuesday as doubts about high-running valuations preyed on investors sifting through the latest flurry of quarterly earnings. Meanwhile, Norway's sovereign wealth fund said it will ...

The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after ...

Tech stocks led a selloff in the first minutes of trading on Monday as doubts about high-running valuations preyed on ...

Oil prices fell more than 1% on Tuesday as the OPEC+ decision to pause output hikes in the first quarter of next year, along with weak manufacturing data and a stronger dollar, weighed on the market.

Novo Nordisk and Pfizer have revised their bids for Metsera, the obesity drug developer said on Tuesday. Novo's revised offer ...

Ferrari has trimmed price increases on some of the models it sells in the U. to a maximum of 5% following a deal to reduce ...

Novo Nordisk is now offering up to $10 billion for Metsera, up from its prior offer of up to $8.5 billion, the obesity drug ...

BERLIN (Reuters) -German defence giant Rheinmetall is in the final stages of negotiating a multi-billion-euro ammunitions ...

Deutsche Telekom and Nvidia are launching an AI cloud for industrial applications in a 1 billion euro ($1.2 billion) ...

Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, Nov. 4: Universal Health Services, Inc. UHS: This operator of hospitals, and behavioral health ...